Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Harvard Business School
Baxter
Merck
Colorcon

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AZILECT

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Azilect

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00399477 A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease Completed Teva Neuroscience, Inc. Phase 4 2006-10-01 Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: - Group 1 Patients using Azilect and no other therapy. - Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
NCT00696215 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status Istanbul University Phase 4 2007-06-01 The objective of the study is to assess the effects of rasagiline on cognitive functions in patient with Parkinson's disease. Patients on any dopaminergic medications will be assigned to receive rasagiline 1 mg or placebo over 3 months. Cognitive functions will be assessed by selected neuropsychological tests representing each cognitive domain.
NCT00955604 Azilect + Antidepressant Chart Review Completed Teva Pharmaceutical Industries N/A 2009-07-01 To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD patients receiving antidepressants, but not rasagiline.
NCT01007630 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status Teva Neuroscience, Inc. Phase 4 2009-11-01 A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.
NCT01007630 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status The Parkinson's Institute Phase 4 2009-11-01 A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.
NCT01032486 Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease Completed Teva Pharmaceutical Industries Phase 4 2009-12-01 The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.
NCT01055379 Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn Completed Teva Pharmaceutical Industries Phase 4 2010-03-01 The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Azilect

Condition Name

Condition Name for Azilect
Intervention Trials
Parkinson's Disease 14
Parkinson Disease 3
Sleep Disturbances 1
Parkinson´s Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Azilect
Intervention Trials
Parkinson Disease 20
Cognition Disorders 2
Dyssomnias 1
Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Azilect

Trials by Country

Trials by Country for Azilect
Location Trials
United States 25
Germany 4
China 3
Italy 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Azilect
Location Trials
New York 3
Florida 3
Pennsylvania 2
Ohio 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Azilect

Clinical Trial Phase

Clinical Trial Phase for Azilect
Clinical Trial Phase Trials
Phase 4 11
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Azilect
Clinical Trial Phase Trials
Completed 14
Terminated 3
Unknown status 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Azilect

Sponsor Name

Sponsor Name for Azilect
Sponsor Trials
Teva Pharmaceutical Industries 5
Teva Neuroscience, Inc. 4
H. Lundbeck A/S 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Azilect
Sponsor Trials
Industry 19
Other 15
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
McKinsey
AstraZeneca
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.